Results of treatment for male prolactinomas

被引:0
|
作者
Iwai, Y [1 ]
Yamanaka, K [1 ]
Ishiguro, T [1 ]
Morikawa, T [1 ]
Matsuzaka, Y [1 ]
Komiyama, M [1 ]
Yasui, T [1 ]
机构
[1] Osaka City Gen Hosp, Dept Neurosurg, Miyakojima Ku, Osaka 5340021, Japan
来源
NEUROLOGICAL SURGERY | 2002年 / 30卷 / 12期
关键词
prolactinoma; male; bromocriptine; dopamine agonist; pituitary gland;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We evaluated the results of medical treatment for male prolactinomas. We encountered eight patients with male prolactinomas. The age was 25 to 54 years old (mean 43 years) and the chief clinical symptoms were visual acuity/field defect in three patients, pituitary apoplexy in one patient, disturbance of ejection in one patient, generalized convulsion in one patient, headache in one patient and general fatigue in one patient. The serum prolactin level was 279 to 7,360ng/ml (mean 2,832ng/ml). The tumors in all patients were large with a mean diameter of 34.9mm (range, 21 to 43mm). In only one patient, the operation was performed due to pituitary apoplexy. All the patients were treated by medication, with bromocriptine being used in seven patients and, terguride in one. The follow-up period was 0.8 to 13 years (mean 5.9 years) and, in all patients, the medical treatment was continued. The tumor decreased in size in all patients and the serum prolactin level at the last follow-up observation was 0.5 to 70.5ng/ml (mean 26.9ng/ml). All the neurological symptoms disappeared in the early stage of treatment., As for the complications of medical treatment; in one patient, orthostatic hypotension occurred during the initial administration of bromocriptine and one patient suffered CSF leakage two months after the administration of bromocriptine, so the repair of the sella floor by transsphenoidal surgery was necessary. The medical treatment for male prolactinomas is effective for a long term and should be the primary treatment for the male prolactinomas. In conclusion, patients can maintain a good quality of life for a long time by using dopamine agonists
引用
收藏
页码:1285 / 1292
页数:8
相关论文
共 50 条
  • [21] Prolactinomas: diagnosis and treatment
    Delemer, Brigitte
    PRESSE MEDICALE, 2009, 38 (01): : 117 - 124
  • [22] Medical treatment of prolactinomas
    Molitch, ME
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (01) : 143 - +
  • [23] Male prolactinomas presenting with normal testosterone levels
    Ilan Shimon
    Carlos Benbassat
    Pituitary, 2014, 17 : 246 - 250
  • [24] Male prolactinomas presenting with normal testosterone levels
    Shimon, Ilan
    Benbassat, Carlos
    PITUITARY, 2014, 17 (03) : 246 - 250
  • [25] PREVALENCE OF CLINICALLY APPARENT PROLACTINOMAS IN THE SUBFERTILE MALE
    Darves-Bornoz, Anne
    Patel, Mehul
    Keeter, Mary Kate
    Wren, James
    Bennett, Nelson
    Halpern, Joshua
    Brannigan, Robert
    JOURNAL OF UROLOGY, 2020, 203 : E401 - E402
  • [26] Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients
    Kreutzer, J.
    Buslei, R.
    Wallaschofski, H.
    Hofmann, B.
    Nimsky, C.
    Fahlbusch, R.
    Buchfelder, M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (01) : 11 - 18
  • [27] PROLACTINOMAS - SURGICAL THERAPY, INDICATIONS AND RESULTS
    RAWE, SE
    WILLIAMSON, HO
    LEVINE, JH
    PHANSEY, SA
    HUNGERFORD, D
    ADKINS, WY
    SURGICAL NEUROLOGY, 1980, 14 (03): : 161 - 167
  • [28] Transsphenoidal surgery for prolactinomas: results and prognosis
    Sinkunas, Kestutis
    Rastenyte, Daiva
    Deltuva, Vytenis Pranas
    Knispelis, Robertas
    Tamasauskas, Arimantas
    MEDICINA-LITHUANIA, 2007, 43 (09): : 691 - 697
  • [29] Treatment of prolactinomas by transsphenoidal adenomectomy
    H. Vierhapper
    T. Czech
    C. Matula
    W. Raber
    Journal of Endocrinological Investigation, 1997, 20 : 431 - 432
  • [30] The treatment of aggressive prolactinomas with everolimus
    Andrew L. Lin
    Eliza B. Geer
    Nupur Lala
    Gabrielle Page-Wilson
    Rajiv Magge
    Robert J. Young
    Viviane Tabar
    Pituitary, 2023, 26 : 474 - 481